Brief: Calithera Biosciences Says Cantata Trial Top-Line Results Expected In H2 Of 2020

Calithera Biosciences

03/10/2019 12:05

Oct 3 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES COMPLETES PATIENT ENROLLMENT IN
RANDOMIZED
CANTATA TRIAL OF TELAGLENASTAT AND CABOZANTINIB IN ADVANCED
RENAL CELL CARCINOMA
    * CALITHERA BIOSCIENCES INC - STUDY TOP-LINE RESULTS
EXPECTED IN
SECOND HALF OF 2020

Source text for Eikon:  ID:nGNX69SDgG 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))